Corporate | 3 July 2007 10:22
WILEX AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
SAVE THE DATE: First international symposium on functional and clinical
aspects of the tumour antigen CA-IX to be held on 14 November 2007 in
Brussels
Munich, 3 July 2007. The first international symposium on functional and
clinical aspects of the tumour antigen 'Carbonic Anhydrase IX' (or CA-IX)
will be held on 14 November 2007. The symposium will report on the latest
research findings and clinical developments relating to CA-IX in the areas
of diagnosis, prognosis and therapy.
The event is co-sponsored by the Munich-based biopharmaceutical company
WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard)
and the international Ludwig Institute for Cancer Research (LICR). It will
be held in the Sheraton Hotel in Brussels and participation is free of
charge. Details of the programme and information on how to register can be
found under www.ca-ix.com.
ABOUT CA-IX
Tumour antigens such as CA-IX are becoming increasingly important in the
diagnosis and treatment of cancer. CA-IX is the most specific antigen known
for clear cell renal cell carcinomas, for example and its potential
importance in other tumour types is beginning to be recognised. WILEX AG
has developed a monoclonal antibody (WX-G250, development name RENCAREX®)
which specifically binds to the CA-IX antigen. The drug candidate RENCAREX®
is currently in a clinical Phase III trial to prevent the development of
metastatic disease in kidney cancer patients following partial or complete
removal of the affected kidney.
About WILEX
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a
team of physicians and oncologists from the Technical University of Munich.
WILEX is focused on the development of new cancer therapies based on
antibodies and small molecules. The therapeutic approach of WILEX targets
the prevention of growth, spread and the metastasis of malignant tumours
and the destruction of malignant tumours in the body. The late stage
multi-product portfolio includes both drug and medicinal product candidates
ranging from research to late stage clinical development. Currently the
following compounds are in clinical development: WX-G250 (development name:
RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The Company’s strategy is to
develop WILEX into a commercially successful biopharmaceutical company with
a broad portfolio of new drugs and medical products for the treatment of
cancer. WILEX AG has been listed at the Frankfurt Stock Exchange on the
Official Market Segment (Amtlicher Markt) / Prime Standard since 13
November 2006.
ISIN DE0006614720 / WKN 661472 / Symbol WL6
About LICR
The Ludwig Institute for Cancer Research (LICR) is the largest
international non-profit institute dedicated to understanding and
controlling cancer. With operations at 73 sites in 17 countries, LICR’s
research network quite literally spans the globe. LICR has developed an
impressive portfolio of reagents, knowledge, expertise, and intellectual
property, and has also assembled the personnel, facilities, and practices
necessary to patent, clinically evaluate, license, and thus translate, the
most promising aspects of its own laboratory research into cancer
therapies.
Contact
Sarah L. White, Ph.D.
Director, Office of Communications
605 Third Avenue / 33rd Floor
New York, NY 10158
USA
Tel: +1 917 379 0398
Fax: +1 212 450 1500
E-mail: swhite@licr.org
Website: http://www.licr.org
DGAP 03.07.2007
----------------------------------------------------------------------
Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------